P116 | OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH DOSE-ADJUSTMENT IBRUTINIB: A MONOCENTER-REAL-LIFE STUDY

Background: Clinical studies show IBR's safety and efficacy, but real-world data reveal increased toxicity and interruption rates. Adverse event (AE)-related interruptions occur in 14–29% of cases in clinical practice, compared to 4–9% in Phase III studies. Dose adjustments (DA) in real life a...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	R. Laureana, L. Pupo, V. Gattei, D. Giannarelli, R. Morgagni, F. Esposito, A. Di Veroli, A.G. Parato, A. Nunzi, L. Cardillo, G. Del Poeta, M. Postorino, M.I. Del Principe
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12413